Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.

Pulmonary Fibrosis NI has received a donation of €1,210 made in memory of the late Bart Teague. The cheque was presented by ...

Boston-based biotech Avalyn Pharma is the latest to hop on the IPO train, filing to list on the Nasdaq and raise funds for ...

Pulmonary Fibrosis NI has received a donation of €1,210 made in memory of the late Bart Teague. The cheque was presented by ...

Pulmonary fibrosis is a progressive interstitial lung disease characterized by excessive extracellular matrix deposition, architectural distortion and declining lung function. While epithelial injury ...

Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent ...

The Pulmonary Fibrosis Foundation (PFF) today announced its PFF Walk 2026 schedule as the organization celebrates the 10 (th) season of the national fundraising program, which has raised more than $7.

Avalyn Pharma is eyeing an IPO as the biotech seeks more funds to take its inhaled versions of approved drugs for lung ...

Isolated antineutrophil cytoplasmic antibody-associated interstitial lung disease is an increasingly recognized fibrotic ILD phenotype.

University of Colorado Denver Biomedical Engineering Associate Professor Chelsea Magin is developing a lung model to help ...

Backed by Novo Holdings and multiple other prominent investors, the biotech is developing what it’s positioning as superior ...

Underwriters were given a 30-day option to purchase up to 1.74 million additional shares. ・Trevi is currently developing Haduvio, its treatment for chronic cough in patients with idiopathic pulmonary ...